Royalty Pharma Declares Second-Quarter 2021 Dividend
The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved a dividend payment of $0.17 per class A share for the second quarter of 2021. This dividend will be paid on June 15, 2021, to shareholders on record as of May 20, 2021. Royalty Pharma is recognized as the largest purchaser of biopharmaceutical royalties and plays a significant role in funding innovation in the biopharmaceutical sector, partnering with a range of companies to enhance their product launches and clinical trials.
- Approval of a $0.17 dividend per share reflects confidence in financial health.
- Dividend payment enhances shareholder value and income.
- None.
NEW YORK, April 15, 2021 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2021 of
The dividend will be paid on June 15, 2021, to shareholders of record at the close of business on May 20, 2021.
About Royalty Pharma plc
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 45 commercial products, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s Trodelvy, Merck’s Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. For more information, visit www.royaltypharma.com
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6772
ir@royaltypharma.com
FAQ
What is the dividend payment date for RPRX in 2021?
What is the amount of the dividend approved for RPRX?
Who are the shareholders eligible for the dividend payment by RPRX?
What does Royalty Pharma do?
